Immune activation and disease progression in HIV-1 infection
In humans, the gut-associated lymphoid tissue (GALT) contains a large number of activated CD4 + CCR5 + T cells, thus serving as a major site of viral replication and CD4 + T cell depletion early in the course of HIV-1 infection (1, 2). In contrast to the rapid depletion of intestinal CD4 + T cells, the decline of CD4 + T cells in peripheral blood is much slower and less extensive during acute HIV-1 infection, suggesting that the majority of peripheral CD4 + T cells are nonpermissive at this stage (2, 3). During the chronic phase of infection, systemic immune activation is very strongly correlated with disease progression (4). Activation of CD4 + T cells increases coreceptor expression and renders these cells more susceptible to HIV-1 infection, and these cycles of activation and infection may drive progression of disease to AIDS (5). In contrast, SIV infection in natural host species very rarely progresses to AIDS and does not result in increased levels of immune activation, despite high levels of virus replication (6, 7). Infection and depletion of CD4 + T cells in GALT can be observed in both SIV and HIV-1 infection; however, natural host species infected with SIV do not often develop systemic immune activation, despite loss of GALT CD4 + T cells (6, 7) , suggesting that factors other than direct infection and mucosal CD4 + T cell loss are essential for the increased degree of immune activation seen in HIV-1 infection.
Microbial translocation in HIV-1 infection
Translocation of microbial products from the lumen of the gastrointestinal tract into the circulation often occurs in HIV-1-infected individuals and is closely associated with systemic immune activation. Many studies have shown that HIV-1-infected individuals have elevated plasma levels of LPS and soluble CD14, which is indicative of LPS-induced monocyte and macrophage activation (8) . Plasma levels of other microbial products, such as bacterial DNA and flagellin, are also increased in HIV-1-infected individuals compared with healthy controls (8, 9) . Furthermore, there is a negative correlation between plasma induced gastrointestinal tract damage or restore intestinal CD4 + T cell populations (17, 18) . Microbial translocation still occurs despite suppressed viral replication in cART-treated patients. Plasma LPS levels in HIV-1-infected individuals decline after initiation of cART but remain substantially higher than those seen in uninfected subjects (19) . Plasma LPS and bacteria DNA levels in cART-treated patients are correlated inversely with CD4 + T cell reconstitution in the GALT (9, 20) 
Conclusions and future directions
Current combinational antiretroviral therapy (cART) can suppress HIV-1 replication to undetectable levels; however, long-term cART fails to completely repair viruslevels of LPS and CD4 + T cell counts (10) . The cause of microbial translocation is multifactorial. HIV-1 replicates vigorously in GALT and causes damage to intestinal barrier through several mechanisms. First, HIV-1 infection leads to the production of proinflammatory cytokines, which induce apoptosis of enterocytes and disruption of tight junctions, the epithelial barrier against microbial translocation (11) . A second mechanism involves intestinal Th17 cells, which produce cytokines, including IL-17 and IL-22, to recruit and activate neutrophils as well as promote the release of antimicrobial peptides (12) . Th17 cells are preferentially depleted by direct infection, likely due to the high expression of the CCR5 coreceptor on these cells (13) . As a consequence of viral infection, damage to intestinal epithelial barrier and decreased control of intestinal bacteria result in the translocation of commensal microbial products, including LPS, into circulation. In principle, these products can induce production of proinflammatory cytokines and promote peripheral T cell activation and cycling (Figure 1 ). Microbial translocation occurs during HIV-1 and pathogenic SIV infection but not during SIV infection of natural host species (5), suggesting that microbial translocation may play a role in viral infection and disease progression. Interestingly, intravenous LPS administration in natural host species infected with SIV does induce systemic immune activation, increase SIV replication, and accelerate CD4 + T cell depletion (14) . Mutations that result in constitutively activated EGFR are associated with patient responsiveness to small-molecule EGFR inhibitors in lung cancer; however, these mutations are rarely identified in HNSCC or CRC. Moreover, neither EGFR overexpression nor EGFR amplification predicts clinical benefit from cetuximab (1, 2). The discordance between EGFR target expression and the efficacy of target blockade by cetuximab has broadened investigation into the mechanisms of action and development of therapeutic resistance. Initial strategies to enhance cetuximab activity have focused on the intracellular signaling hypothesis ( Figure 1A ), which suggests that de novo or compensatory activation of parallel RTKs (alternate HER family members, cMet, IGF1R, FGFR, VEGFR), downstream EGFR-signaling nodes (RAS, PI3K, STAT3, SRC), or cell cycle promoters (aurora kinase, CDK4/6) circumvents EGFR blockade in HNSCC preclinical models; therefore, coinhibition of these resistance nodes should enhance the activity of cetuximab (3) . Cetuximab resistance has also been attributed to heterodimerization of EGFR with other HER proteins that potentially prevent recognition of EGFR by cetuximab as well as acquisition of gain-of-function PIK3CA mutations that activate signaling downstream of EGFR. In CRC patients, activating KRAS and BRAF mutations confer clinical cetuximab resistance. Progressive insight into the complexity and plasticity of the EGFR signaling network has propelled cetuximab-combination trials to evaluate the efficacy of cotargeting these purported resistance nodes (Table 1) .
